Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Wednesday, August 21, 2024
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Roche to accelerate Wegovy weight loss rivals after positive trials

July 29, 2024
in News
Reading Time: 2 mins read
A A
Roche to accelerate Wegovy weight loss rivals after positive trials
0
SHARES
ShareShareShareShareShare

READ ALSO

Volatility spike was a ‘huge overreaction,’ but more could be ahead, strategist says

Japan trade on deck, Wall Street rally pauses

Sopa Images | Lightrocket | Getty Images

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data.

The company’s two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years, providing a potential pill-based alternative to Novo Nordisk’s Wegovy and Eli Lilly‘s Zepbound weight loss injections.

“We are fast-tracking the clinical development of our obesity portfolio with the aim to bring these medications to patients faster than anticipated,” the spokesperson told CNBC via email.

The company did not reveal its new timeline, saying it would provide an update “when appropriate.” However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm’s first obesity drug could come to market “significantly faster than people are expecting,” potentially by 2028.

Roche Pharmaceuticals CEO Teresa Graham previously told CNBC in December that she expected the company would be able to bring the products to market from 2030 onwards.

Roche’s CT-388 drug is now entering phase two trials after results published in May pointed to its efficacy in helping patients with obesity lose 18.8% of their weight after 24 weeks relative to those who received a placebo.

The company’s experimental once-daily pill CT-996 will enter phase two tests next year after trials earlier this month showed that it resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without Type 2 diabetes.

Both CT-388 and CT-996 were acquired as part of Roche’s purchase of U.S. biotech company Carmot Therapeutics, which completed in January.

The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Roche to accelerate Wegovy weight loss rivals after positive trials

“We have a number of things in our pipeline that really can differentiate us from other players,” Schinecker told CNBC’s “Squawk Box Europe.”

“We do believe we have two next generation GLP-1/GIPs that have a best in disease potential,” he said of the obesity drugs.

“We also have a number of different medicines in our own portfolio that we can combine with [obesity drugs],” he added, highlighting GYM329 as an example of a drug which counters muscle loss, a key side effect of weight loss.

Credit: Source link

ShareTweetSendSharePin
Previous Post

Bosses are making staff RTO—or quit (but they’re absent themselves)

Next Post

Google’s first cross-device sharing features for Android now rolling out

Related Posts

Volatility spike was a ‘huge overreaction,’ but more could be ahead, strategist says
News

Volatility spike was a ‘huge overreaction,’ but more could be ahead, strategist says

August 21, 2024
Japan trade on deck, Wall Street rally pauses
News

Japan trade on deck, Wall Street rally pauses

August 21, 2024
GMC targets electric truck leadership against Tesla, Ford, Rivian
News

GMC targets electric truck leadership against Tesla, Ford, Rivian

August 21, 2024
Brits snap up lower mortgages as BOE cut boosts market
News

Brits snap up lower mortgages as BOE cut boosts market

August 20, 2024
Eli Lilly weight loss drug cuts risk of developing diabetes in trial
News

Eli Lilly weight loss drug cuts risk of developing diabetes in trial

August 20, 2024
Who is Mike Lynch, UK tech entrepreneur missing in superyacht sinking?
News

Who is Mike Lynch, UK tech entrepreneur missing in superyacht sinking?

August 20, 2024
Next Post
Google’s first cross-device sharing features for Android now rolling out

Google's first cross-device sharing features for Android now rolling out

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

Yankees cough up lead as spiral continues with loss to Red Sox

Yankees cough up lead as spiral continues with loss to Red Sox

July 27, 2024
U.S. crude oil jumps more than 3% after Hamas political leader assassinated in Tehran

U.S. crude oil jumps more than 3% after Hamas political leader assassinated in Tehran

July 31, 2024
Travel is too expensive now — travel demand falls under cost concerns

Travel is too expensive now — travel demand falls under cost concerns

August 20, 2024
The Plucky Squire expertly transforms old ideas into something new

The Plucky Squire expertly transforms old ideas into something new

August 16, 2024
Punches thrown as tempers flare during Jets-Panthers skirmish

Punches thrown as tempers flare during Jets-Panthers skirmish

August 15, 2024
Iranians are creating fake news websites and impersonating activists to create chaos in the U.S., Microsoft found

Iranians are creating fake news websites and impersonating activists to create chaos in the U.S., Microsoft found

August 10, 2024
Mitsubishi .3bn chemical plant in Louisiana doesn’t work

Mitsubishi $1.3bn chemical plant in Louisiana doesn’t work

July 23, 2024

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Volatility spike was a ‘huge overreaction,’ but more could be ahead, strategist says
  • The EU wants no corner of the digital sphere left untouched, warning X and AI could be next
  • Kevin James recreates viral video in electric Mets moment
  • Japan trade on deck, Wall Street rally pauses

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In